Aiyedun, D. orcid.org/0009-0005-0652-9444, Rogers, S.F. orcid.org/0009-0004-0865-6714, Taha, D.M. et al. (1 more author) (2026) Challenges in gene-directed therapies for rare neurodevelopmental disorders using HNRNPU as an exemplar. Clinical Genetics. ISSN: 0009-9163
Abstract
Next-generation sequencing has radically transformed the diagnostic capability of rare neurodevelopmental disorders (RNDDs), yet translating these molecular insights into viable therapeutics remains a hurdle. While gene-directed modalities, specifically viral-mediated supplementation, antisense oligonucleotides (ASOs), and CRISPR-based activation or precision editing, offer a means to rescue loss-of-function phenotypes, successful clinical implementation requires moving past the reductive framework of merely increasing the expression of the target gene towards approaches that account for spatial, developmental, and therapeutic windows. This review uses HNRNPU-related rare neurodevelopmental disorder (HNRNPU-RNDD), a condition marked with global developmental delay and refractory epilepsy, as an exemplar to discuss these translational hurdles. We discuss the homeostatic boundaries of this scaffold attachment factor, where unregulated overexpression risks localised cytotoxicity, and altered chromatin dynamics compromise editing safety. Furthermore, we assess how cell-type sensitivity and narrow developmental windows may dictate clinical efficacy. By using HNRNPU-RNDD to critically analyse the challenges of using each therapeutic platform, we hope to inform the creation of gene-directed therapies that aim to treat disorders resulting from structural pleiotropic dosage-sensitive proteins.
Metadata
| Item Type: | Article |
|---|---|
| Authors/Creators: |
|
| Copyright, Publisher and Additional Information: | © 2026 The Author(s). Clinical Genetics published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | AAV9; antisense oligonucleotide; epilepsy; gene therapy; haploinsufficiency; HNRNPU; loss-of-function; nuclear matrix; rare neurodevelopmental disorder |
| Dates: |
|
| Institution: | The University of Sheffield |
| Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > The Medical School (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology and Metabolism (Sheffield) The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health |
| Date Deposited: | 28 Oct 2026 16:52 |
| Last Modified: | 28 Oct 2026 16:52 |
| Status: | Published online |
| Publisher: | Wiley |
| Refereed: | Yes |
| Identification Number: | 10.1111/cge.70267 |
| Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:247192 |

CORE (COnnecting REpositories)
CORE (COnnecting REpositories)